Boston Scientific Corp (BSX) stock
BSXNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 14/3051% below fair value
$44.34+0.14 (+0.32%)
Close on Nov 13, 2026Market cap $64.26BP/E 18.8Yield –
Boston Scientific r&d expenses
Research and development expenses are spending on new products and technology.
Boston Scientific's R&D Expenses for the twelve months ending Sep 30, 2026 was $2.16B, up 11.2% year over year. For fiscal 2025 it was $2.05B, up 27.1% from the year before. Over ten years it grew 8.9% a year on average. The highest annual figure on record is $2.05B in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.05B | +27.1% |
| FY2024 | Dec 31, 2024 | $1.62B | +14.2% |
| FY2023 | Dec 31, 2023 | $1.41B | +6.9% |
| FY2022 | Dec 31, 2022 | $1.32B | +9.9% |
| FY2021 | Dec 31, 2021 | $1.20B | +5.3% |
| FY2020 | Dec 31, 2020 | $1.14B | -2.6% |
| FY2019 | Dec 31, 2019 | $1.17B | +5.5% |
| FY2018 | Dec 31, 2018 | $1.11B | +11.6% |
| FY2017 | Dec 31, 2017 | $997.00M | +8.4% |
| FY2016 | Dec 31, 2016 | $920.00M | +5.0% |
| FY2015 | Dec 31, 2015 | $876.00M | +7.2% |
| FY2014 | Dec 31, 2014 | $817.00M | -5.1% |
| FY2013 | Dec 31, 2013 | $861.00M | -2.8% |
| FY2012 | Dec 31, 2012 | $886.00M | -1.0% |
| FY2011 | Dec 31, 2011 | $895.00M | -4.7% |
| FY2010 | Dec 31, 2010 | $939.00M | -9.3% |
| FY2009 | Dec 31, 2009 | $1.04B | +2.9% |
| FY2008 | Dec 31, 2008 | $1.01B | -7.8% |
| FY2007 | Dec 31, 2007 | $1.09B | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $520.00M | +1.2% |
| Q2 FY2026 | Jun 30, 2026 | $554.00M | +5.3% |
| Q1 FY2026 | Mar 31, 2026 | $516.00M | +16.5% |
| Q4 FY2025 | Dec 31, 2025 | $569.00M | +24.0% |
| Q3 FY2025 | Sep 30, 2025 | $514.00M | +26.3% |
| Q2 FY2025 | Jun 30, 2025 | $526.00M | +37.3% |
| Q1 FY2025 | Mar 31, 2025 | $443.00M | +21.0% |
| Q4 FY2024 | Dec 31, 2024 | $459.00M | +26.4% |
| Q3 FY2024 | Sep 30, 2024 | $407.00M | +14.3% |
| Q2 FY2024 | Jun 30, 2024 | $383.00M | +6.7% |
| Q1 FY2024 | Mar 31, 2024 | $366.00M | +8.6% |
| Q4 FY2023 | Dec 31, 2023 | $363.00M | +10.0% |
| Q3 FY2023 | Sep 30, 2023 | $356.00M | +5.0% |
| Q2 FY2023 | Jun 30, 2023 | $359.00M | +7.2% |
| Q1 FY2023 | Mar 31, 2023 | $337.00M | +5.6% |
| Q4 FY2022 | Dec 31, 2022 | $330.00M | +3.1% |
| Q3 FY2022 | Sep 30, 2022 | $339.00M | +9.4% |
| Q2 FY2022 | Jun 30, 2022 | $335.00M | +12.4% |
| Q1 FY2022 | Mar 31, 2022 | $319.00M | +15.6% |
| Q4 FY2021 | Dec 31, 2021 | $320.00M | +11.9% |
| Q3 FY2021 | Sep 30, 2021 | $310.00M | -1.6% |
| Q2 FY2021 | Jun 30, 2021 | $298.00M | +23.1% |
| Q1 FY2021 | Mar 31, 2021 | $276.00M | -8.0% |
| Q4 FY2020 | Dec 31, 2020 | $286.00M | -7.1% |
| Q3 FY2020 | Sep 30, 2020 | $315.00M | +2.9% |
| Q2 FY2020 | Jun 30, 2020 | $242.00M | -13.6% |
| Q1 FY2020 | Mar 31, 2020 | $300.00M | +7.1% |
| Q4 FY2019 | Dec 31, 2019 | $308.00M | +6.9% |
| Q3 FY2019 | Sep 30, 2019 | $306.00M | +5.9% |
| Q2 FY2019 | Jun 30, 2019 | $280.00M | +1.8% |
| Q1 FY2019 | Mar 31, 2019 | $280.00M | +7.3% |
| Q4 FY2018 | Dec 31, 2018 | $288.00M | +9.5% |
| Q3 FY2018 | Sep 30, 2018 | $289.00M | +13.8% |
| Q2 FY2018 | Jun 30, 2018 | $275.00M | +12.7% |
| Q1 FY2018 | Mar 31, 2018 | $261.00M | +11.1% |
| Q4 FY2017 | Dec 31, 2017 | $263.00M | +2.7% |
| Q3 FY2017 | Sep 30, 2017 | $254.00M | – |
| Q2 FY2017 | Jun 30, 2017 | $244.00M | – |
| Q1 FY2017 | Mar 31, 2017 | $235.00M | – |
| Q4 FY2016 | Dec 31, 2016 | $256.00M | – |
See a number that looks wrong?